HLA Genetic Diversity and Chronic Hepatitis B Virus Infection: Effect of Heterozygosity Advantage
Medical Sciences · 2024
DOI: 10.3390/medsci12030044 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical Sciences, 2024. Verfasst von Adriana Tălăngescu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Immunology and Transplant Immunology, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Heterozygote, Genetic Variation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
This research aims to determine whether HLA heterozygosity confers a protective effect against hepatitis B virus infection by analyzing the relationship between HLA diversity and the risk of hepatitis B virus (HBV) infection. A total of 327 hepatitis B patients were selected and categorized based on their clinical status: 284 patients with chronic HBV infection and 43 patients with HBV-related liver cirrhosis (LC). The control group included 304 healthy individuals. HLA genotyping for 11 loci, including HLA class I and class II, was conducted using next-generation sequencing. The results of this study indicate a statistically significant negative correlation between HLA class II heterozygosity and the risk of HBV infection. Specifically, heterozygosity in HLA-DQB1 (OR = 0.49, 95% CI = 0.31–0.76, p = 0.01277) and HLA-DRB1 (OR = 0.42, 95% CI = 0.24–0.77, p = 0.01855) were significantly associated with protection. Subgroup analysis was conducted to explore the effect of HLA diversity among pathological subtypes (chronic hepatitis B and control group, liver cirrhosis and control group). For liver cirrhosis, compared with the control group, a decreased risk of LC was possibly associated with the heterozygosity of HLA class I locus B (OR = 0.24, 95% CI = 0.09–0.65, p = 0.0591), but this hypothesis was not confirmed by other studies. The diversity of HLA, measured by HLA heterozygosity, was associated with a protective effect against HBV infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Immunology and Transplant Immunology, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.
- Centre of Immunogenetics and Virology, Fundeni Clinical Institute, 258 Fundeni Avenue, 022328 Bucharest, Romania.
- Department of Anatomy, Animal Physiology and Biophysics, Faculty of Biology, University of Bucharest, Splaiul Independentei Street, No. 91-95, 050095 Bucharest, Romania.
- "Emil Palade" Centre of Excellence for Young People in Scientific Research (EP-CEYR), 3 Ilfov Street, Sector 5, 050045 Bucharest, Romania.
- Academy of Romanian Scientists (AOSR), 3 Ilfov Street, Sector 5, 050045 Bucharest, Romania.
ORCID-Profile: Maria Tizu, Dan Florin Mihăilescu, Ileana Constantinescu
Zitieren
APA
Tălăngescu, A., Tizu, M., Calenic, B., Mihăilescu, D. F., Constantinescu, A. E., & Constantinescu, I. (2024). HLA Genetic Diversity and Chronic Hepatitis B Virus Infection: Effect of Heterozygosity Advantage. Medical Sciences. https://doi.org/10.3390/medsci12030044
Vancouver
Tălăngescu A, Tizu M, Calenic B, Mihăilescu DF, Constantinescu AE, Constantinescu I. HLA Genetic Diversity and Chronic Hepatitis B Virus Infection: Effect of Heterozygosity Advantage. Medical Sciences. 2024. doi:10.3390/medsci12030044
BibTeX
@article{Tlngescu2024,
author = {Tălăngescu, Adriana and Tizu, Maria and Calenic, Bogdan and Mihăilescu, Dan Florin and Constantinescu, Alexandra Elena and Constantinescu, Ileana},
title = {HLA Genetic Diversity and Chronic Hepatitis B Virus Infection: Effect of Heterozygosity Advantage},
journal = {Medical Sciences},
year = {2024},
doi = {10.3390/medsci12030044}
}
EUVIMED